Repare Therapeutics Stock Forum

$Mill City Ventures III (MCVT.US)$ $Jowell Global (JWEL.US)$ $NCI (01336.HK)$ $Onconetix (ONCO.US)$ $YXT.COM Group Holding (YXT.US)$ $Cognition Therapeutics (CGTX.US)$ $Ambow Education (AMBO.US)$ $Matinas BioPharma (MTNB.US)$ $TCTM Kids IT Education (TCTM.US)$ $N2OFF (NITO.US)$ $Repare Therapeutics (RPTX.US)$ $ZK International (ZKIN.US)$
📊⚡️📊

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Repare Therapeutics (Nasdaq: RPTX) presented Phase 1 data at the ASTRO Annual Meeting, showcasing the potential of camonsertib, an oral ATR inhibitor, combined with palliative radiation for treating metastatic tumors with ATM mutations.
The study enrolled 17 patients, 12 with pathogenic ATM mutations and 5 with va...

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
Repare Therapeutics presented new data at AACR's Ovarian Cancer Research Symposium, highlighting the impact of FBXW7, PPP2R1A, and CCNE1 alterations in metastatic ovarian and endometrial cancers. The analysis of approximately 2,000 patients revealed:
1. Ovarian cancer: Patients with these biomarkers (Lunre BM+) had a media...

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Repare Therapeutics (Nasdaq: RPTX) announced a strategic reprioritization to focus on its clinical-stage oncology programs. The company plans to reduce its workforce by 25%, primarily from the preclinical group, expecting annual savings of $15 million and extending its cash runway into H2 2026. Key highlights include:
1. Upcoming data from the MYTHIC trial(lunresertib ...

$Repare Therapeutics (RPTX.US)$ ⏰静待股价回落，📌首轮加仓价@3.21🔥
——参考资讯——
🔺Repare Therapeutics is a clinical-stage precision oncology company that focuses on developing novel cancer therapies using a synthetic lethality approach. The company leverages its proprietary SNIPRx® platform, which employs genome-wide CRISPR-based screening to identify synthetic lethal gene pairs. This allows them to target specific genetic alterations in tumors, thereby developing highly targeted therapies for cancer patients (http...

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Repare Therapeutics announced positive initial data from their Phase 1 MINOTAUR trial, evaluating lunresertib in combination with FOLFIRI for advanced solid tumors.
The trial showed an overall response rate of 18.2% in heavily pretreated patients and a 51.5% clinical benefit rate. Among colorectal cancer (CRC) patients,...

$Repare Therapeutics (RPTX.US)$ Moving up from yesterdays FDA news

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer